May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Reversal of Established Autoimmune Uveitis Upon Blockade of the Lfa-1/Intercellular Adhesion Molecule-1 (icam-1) Pathway
Author Affiliations & Notes
  • Y. Ke
    University of Louisville, Louisville, Kentucky
  • Footnotes
    Commercial Relationships Y. Ke, None.
  • Footnotes
    Support NIH grants NEI EY12974 (HS), EY14599 (HS), and NEI-EY014366 (DS),Vision Research Infrastructure Development (R24 EY015636), RPB career development award (HS), grant RG3413A4 from the National Multiple
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2633. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Ke; Reversal of Established Autoimmune Uveitis Upon Blockade of the Lfa-1/Intercellular Adhesion Molecule-1 (icam-1) Pathway. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2633.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To identify costimulatory molecules that are important for the effector phase of experimental autoimmune uveitis. (EAU).

Methods:: EAU was induced in C57BL/6 (B6) mice by transfer of activated T cells specific for interphotoreceptor binding protein (IRBP) 1-20 peptide. The animals were then treated with and without anti-LFA-1 mAb, at day 0 or day 10 (disease onset) post-T cell transfer. Clinical signs of inflammation, ocular histology and infiltrated inflammatory cells in the eye were compared. The primary and secondary proliferative responses of uveitogenic CD4 and CD8 T cells were tested after treatment with costimulatory blockers in vivo and in vitro. Moreover, the abilities of uveitogenic T cell trafficking, and their interaction with retinal astrocytes were also examined.

Results:: Anti LFA-1 Abs cause significant suppression of disease when administered either at the time of effector uveitogenic T cell transfer or at disease onset. Studies of the mechanisms by which anti-LFA-1 Ab inhibits the effector phase of uveitis demonstrated that it blocks multiple pathogenic events of uveitis mediated by IRBP-specific uveitogenic T cells, including the activation of T cells outside and inside the eye and the trafficking of activated autoreactive T cells into the inflammatory site. In addition, Ab treatment selectively suppressed the activation and expansion of pathogenic, but not regulatory, T cells in vivo.

Conclusions:: Anti-LFA-1 Abs are potent inhibitors of established autoimmune uveitis and that such treatment may be applicable not only for the prevention, but also the treatment, of T cell-mediated autoimmune diseases.

Keywords: autoimmune disease • uveitis-clinical/animal model 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.